Form 4 holding
CEO and President, Director
Braveheart Bio, Inc.
- Security class
- Common Stock
- Shares / value
- 3,338,175
- Estimated value
- Report date
- 05 Aug 2026
- Price
- Ownership
- By Murdoch Family Trust
Travis Murdoch
Insider Reports History
- Reporting-owner location
- San Carlos, CA
- Latest reporting-owner signature
-
/s/ James Paul Rickey, Attorney-in-Fact
Source: Latest parsed Forms 3/4/5 signature
- Transaction source note
- Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.
Identity
Names, identifiers, and filing context for this profile.
1 identity field
SEC source record
Original filing metadata and source links for verification.
1 source field
Source evidence
Original filing metadata and source links for verification.
1 source field
Reported holdings for Travis Murdoch
Form 4 holding
CEO and President, Director
Braveheart Bio, Inc.
- Security class
- Common Stock
- Shares / value
- 2,940,670
- Estimated value
- Report date
- 07 Aug 2026
- Price
- Ownership
- Direct
Form 4 holding
CEO and President, Director
Braveheart Bio, Inc.
- Security class
- Common Stock
- Shares / value
- 1,027,396
- Estimated value
- Report date
- 05 Aug 2026
- Price
- Ownership
- By Irrevocable Gift Trust for Alizee
Form 4 holding
CEO and President, Director
Braveheart Bio, Inc.
- Security class
- Common Stock
- Shares / value
- 1,027,396
- Estimated value
- Report date
- 05 Aug 2026
- Price
- Ownership
- By Irrevocable Gift Trust for Siena
Form 4 holding
CEO and President, Director
Braveheart Bio, Inc.
- Security class
- Stock Option (Right to Buy)
- Shares / value
- 550,000
- Estimated value
- Report date
- 05 Aug 2026
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
Zymergen Inc.
- Security class
- Common Stock
- Shares / value
- 0
- Estimated value
- Report date
- 19 Oct 2022
- Price
- $2.80
- Ownership
- Direct
Insider Reports Filed by Travis Murdoch
4
BRVE
Braveheart Bio, Inc.
- Report period
- 05 Aug 2026
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 07 Aug 2026, 16:30
- Role
- CEO and President, Director
- Next action
- Open filing details
3
BRVE
Braveheart Bio, Inc.
- Report period
- 05 Aug 2026
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 05 Aug 2026, 21:07
- Role
- CEO and President, Director, 10%+ Owner
- Next action
- Open filing details
4
Zymergen Inc.
- Report period
- 19 Oct 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 19 Oct 2022, 19:48
- Role
- Director
- Next action
- Open filing details
4
Zymergen Inc.
- Report period
- 02 Jun 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 06 Jun 2022, 19:25
- Role
- Director
- Next action
- Open filing details
4
Zymergen Inc.
- Report period
- 14 Feb 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 16 Feb 2022, 16:51
- Role
- Director
- Next action
- Open filing details